Management of Biochemical Failure of Prostate Cancer after Radical prostatectomy: Recent Advances and Future Opportunities
Journal Title: Journal of Oncology and Cancer Research - Year 2017, Vol 1, Issue 1
Abstract
Prostate cancer is the most common new cancer diagnosis and the third leading cause of cancer death in men in the United States. With the use of prostate-specific antigen (PSA) as a screening test, most new prostate cancers are diagnosed when the disease is localized. Standard definitive treatment options for localized prostate cancer include radical prostatectomy (RP) or radiation therapy (RT). The addition of androgen deprivation therapy to RT has been shown to improve treatment outcomes for intermediate and high risk prostate cancers. For patients who undergo RP, the PSA level should be undetectable after the surgery. However, more than a third of patients would develop recurrence of disease, which initially presents with an increase in the PSA to detectable level. The majority of these patients would have no suspicious findings in diagnostic work-up including clinical examination and imaging studies, and the condition is categorized as biochemical failure (BF). Without salvage treatment, the disease would progress to the development of local recurrence or distant metastasis that can be eventually detected clinically. However, the pace of disease progression is variable and may take many years before sites of recurrence can be identified. Management options for patients with BF include salvage radiation therapy, androgen deprivation therapy, and watchful waiting. Salvage radiation therapy is the only treatment that can potentially achieve a cure of the disease. Despite salvage RT, further relapse occurs in > 50% of these patients. Risk factors associated with further relapse include a short time interval from RP to biochemical relapse, PSA level at the time of salvage RT > 1 ng/ml, short PSA doubling time, and presence of seminal vesicle involvement.
Authors and Affiliations
William W. Wong
Keywords
Related Articles
- EP ID EP249327
- DOI 10.28967/jocr.2017.01.17007
- Views 121
- Downloads 0
Have Cluster Randomised Trials a Role in Health Care Research?
Cluster Randomised trials, where groups of individuals are randomised to different treatments and outcomes measured on individuals, have many limitations inherent in the trial design. Selection bias can be introduced int...
Endothelin Signaling as Target for Anticancer Therapy: from Prostate Cancer to Multiple Myeloma
Neuropeptides including endothelin 1 (ET-1) are potent mitogens for both benign and malignant cells through G-protein receptor binding and signal transduction [1]. Aberrant expression of several components of the endothe...
Evaluation of Phosphorylated Proteins Involved in the Epidermal Growth Factor Receptor (EGFR) Signaling Pathway to Predict the Response of Patients with Breast Cancer to Neoadjuvant Chemotherapy Regimens with Weekly Paclitaxel: Preliminary Analysis
This preliminary analysis aimed at evaluating the capacity of epidermal growth factor receptor (EGFR) signaling pathway phosphorylated proteins as predictors of the pathologic response of breast cancer patients treated w...
Effect of Radiotherapy on Antioxidant Vitamin E in Patients with Carcinoma Uterine Cervix- a Pilot Study
Vitamin E, a fat-soluble antioxidant, stops the production of Reactive Oxygen Species (ROS) during the process of fat oxidation. It is used to prevent and repair normal tissue damage and to increase the susceptibility of...
The Epigenetic Theory of Carcinogenesis: p53 as the Guardian of The Epigenome
The principal advantage of the hypothesis that the multiple phenotypic abnormalities characteristic of malignant and pre-malignant cells result from epigenetic disorder is that it accounts for the wide spectrum of anomal...